Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 5Phase 1/2 4Phase 1 2

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Gastrointestinal 2

Conditions

Breast Neoplasms 3Stomach Neoplasms 1HER2-expressing Cancers 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × zanidatamab × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT07494448 2026-04-23

JAZMINE

MedSIR

Phase 1/2 Not yet recruiting
24 enrolled
Breast

Breast Neoplasms

NCT05027139 2025-10-16

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Jazz Pharmaceuticals

Phase 1/2 Completed
52 enrolled

HER2-expressing Cancers

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

BeiGene

Phase 1/2 Completed
71 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡